Skip to main content

Table 1 Distribution of patients on the basis of clinicopathological features and time delay

From: Waiting time for radiation therapy after breast-conserving surgery in early breast cancer: a retrospective analysis of local relapse and distant metastases in 615 patients

Variable N ≤60 days N 60–120 days N >120 days p value
N. group   53   298   264  
Age
 ≤50 53 31 (58.49) 298 85 (28.52) 264 56 (21.21) <0.0001
 >50 53 22 (41.51) 298 213 (71.48) 264 208 (78.79)
Grading
 G1 32 9 (28.13) 228 63 (27.63) 219 71 (32.42) 0.741
 G2 32 20 (62.50) 228 132 (57.89) 219 118 (53.88)
 G3 32 3 (9.38) 228 33 (14.47) 219 30 (13.70)
Hystologic type
 Ductal infiltrating 52 39 (75.00) 297 225 (75.76) 264 176 (66.67) 0.2576
 Lobular infiltrating 52 5 (9.62) 297 16 (5.39) 264 21 (7.95)
 Ductal in situ 52 4 (7.69) 297 32 (10.77) 264 35 (13.26)
 Other 52 4 (7.69) 297 24 (8.08) 264 32 (12.12)
Margins
 Negative 53 52 (98.11) 298 292 (97.99) 264 251 (95.08) 0.0716
 Close 53 0 (0.00) 298 3 (1.01) 264 1 (0.38)
 Positive 53 1 (1.89) 298 3 (1.01) 264 12 (4.55)
Hormone therapy
 No 34 3 (8.82) 258 14 (5.43) 239 21 (8.79) 0.323
 Yes 34 31 (91.18) 258 244 (94.57) 239 218 (91.21)
Estrogen receptor status
 Negative 35 2 (5.71) 267 14 (5.24) 248 17 (6.85) 0.7418
 Positive 35 33 (94.29) 267 253 (94.76) 248 231 (93.15)
Site
 Right breast 53 24 (45.28) 291 140 (48.11) 257 139 (54.09) 0.2778
 Left breast 53 29 (54.72) 291 151 (51.89) 257 118 (45.91)
T stage
 DCIS 53 5 (9.43) 298 44 (14.77) 264 52 (19.70) 0.2187
 T1 53 38 (71.70) 298 216 (72.48) 264 180 (68.18)
 T2 53 10 (18.87) 298 38 (12.75) 264 32 (12.12)
Hormone therapy type
 None 33 3 (9.09) 258 14 (5.43) 239 21 (8.79) 0.0006
 AI 33 5 (15.15) 258 117 (45.35) 239 128 (53.56)
 Tamoxifen 33 14 (42.42) 258 85 (32.95) 239 58 (24.27)
 LHRH + tamoxifen 33 11 (33.33) 258 42 (16.28) 239 32 (13.39)
Year of diagnosis
 1980–1995 53 16 (30.19) 298 12 (4.03) 264 3 (1.14) <0.0001
 1996–2010 53 37 (69.81) 298 286 (95.97) 264 61 (98.86)
  1. N number of patients; AI aromatase Inhibitors; LHRH luteinizing hormone-releasing hormone agonists